Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Total Non-Current Liabilities (2016 - 2025)

Standard Biotools (LAB) has disclosed Total Non-Current Liabilities for 16 consecutive years, with $138.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 27.23% to $138.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $138.8 million, a 27.23% decrease, with the full-year FY2024 number at $139.6 million, down 12.12% from a year prior.
  • Total Non-Current Liabilities was $138.8 million for Q3 2025 at Standard Biotools, up from $131.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $468.4 million in Q2 2023 to a low of $121.5 million in Q1 2025.
  • A 5-year average of $185.3 million and a median of $166.0 million in 2022 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: soared 182.11% in 2023, then tumbled 57.95% in 2024.
  • Standard Biotools' Total Non-Current Liabilities stood at $179.7 million in 2021, then decreased by 11.22% to $159.6 million in 2022, then dropped by 0.48% to $158.8 million in 2023, then decreased by 12.12% to $139.6 million in 2024, then decreased by 0.56% to $138.8 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Total Non-Current Liabilities are $138.8 million (Q3 2025), $131.2 million (Q2 2025), and $121.5 million (Q1 2025).